Roundtable participants highlight need for predictable demand, transparency and collaboration as the foundation of a sustainable U.S. drug supply chain.

The API Innovation Center (APIIC), a nonprofit corporation and public benefit organization dedicated to ensuring a stable U.S.-based supply of active pharmaceutical ingredients (APIs), today announced the release of its new paper, Cross-Sector Insights Into the Drug Supply Chain: Strengthening Domestic Resilience Through Public-Private Partnerships.

The report draws on insights from a roundtable discussion hosted by APIIC in August 2025. It underscores the urgent need for greater resilience in the U.S. drug supply chain — where more than 250 medicines currently in shortage nationwide remain a critical threat to patient care — and emphasizes that the most effective solutions will come from sustained collaboration across the public and private sectors.

Leaders representing pharmaceutical manufacturing, hospital systems, retail pharmacies, government and the economic sector came together for the roundtable. The discussion centered on identifying what each stakeholder needs to support a more reliable domestic drug supply chain and what they are prepared to contribute to achieve it.

“The real value of this paper lies in its process — convening key stakeholders and distilling the essential conditions needed for successful partnerships and long-term resilience,” said Kevin Webb, president and COO of APIIC. “Public-private partnerships are the path forward. If we are serious about safeguarding national health security, collaboration and transparency must be the foundation.”

Identifying What’s Needed — And What’s Next

The paper outlines the priorities raised by participants, including:

• Predictable demand and long-term contracts to de-risk private investment in U.S. manufacturing.
• A shift from lowest-cost purchasing to value-based models that reward reliability and quality.
• Greater transparency across the supply chain to enable smarter decisions and risk management.
• Broad stakeholder engagement to align incentives and ensure reliable access to critical medicines.

These priorities not only define what panelists believe is required for successful collaboration, they also lay the groundwork for discussions at APIIC’s upcoming plenary event in November. There, a broader cross-section of stakeholders will continue to build on what was uncovered in this paper to shape future actionable strategies. Insights from the event will inform APIIC’s next white paper, to be released in 2026.

About the API Innovation Center

The API Innovation Center (APIIC) is a 501(c)(3) nonprofit corporation and public benefit organization dedicated to ensuring a stable, U.S.-based supply of active pharmaceutical ingredients. Through public-private partnerships, APIIC unites government, industry and academia to strengthen national health security, advance novel technology and optimize underutilized manufacturing facilities. Our mission is to ensure that every hospital, pharmacy and patient has access to domestically produced critical medication. APIIC is supported by grants awarded through the state of Missouri and the Missouri Department of Economic Development. To learn more, visit apicenter.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251006093341/en/

Public-private partnerships are the path forward. If we are serious about safeguarding national health security, collaboration and transparency must be the foundation.